Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

1. Ionis reported adjusted earnings of 85 cents, exceeding analysts' loss expectations. 2. Revenue doubled to $452 million, driven by Tryngolza and R&D revenues. 3. Tryngolza generated $19 million in sales during its second quarter on the market. 4. 2025 sales guidance raised to $825-$850 million, higher than consensus estimates. 5. Significant cash reserves at $2 billion position the company favorably for growth.